Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review

Abstract

Lung involvement in systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) has extensively been outlined with a multiplicity of different manifestations. In SLE, the most frequent finding is pleural effusion, while in pSS, airway disease and parenchymal disorders prevail. In both cases, there is an increased risk of pre-capillary and post-capillary pulmonary arterial hypertension (PAH) and pulmonary venous thromboembolism (VTE). The risk of VTE is in part due to an increased thrombophilic status secondary to systemic inflammation or to the well-established association with antiphospholipid antibody syndrome (APS). The lung can also be the site of an organ-specific complication due to the aberrant pathologic immune-hyperactivation as occurs in the development of lymphoma or amyloidosis in pSS. Respiratory infections are a major issue to be addressed when approaching the differential diagnosis, and their exclusion is required to safely start an immunosuppressive therapy. Treatment strategy is mainly based on glucocorticoids (GCs) and immunosuppressants, with a variable response according to the primary pathologic process. Anticoagulation is recommended in case of VTE and multi-targeted treatment regimens including different drugs are the mainstay for PAH management. Antibiotics and respiratory physiotherapy can be considered relevant complement therapeutic measures. In this article, we reviewed lung manifestations in SLE and pSS with the aim to provide a comprehensive overview of their diagnosis and management to physicians taking care of patients with connective tissue diseases.

Keywords

primary Sjogren’s syndrome pulmonary involvement systemic inflammation systemic lupus erythematosus therapeutic strategies

Introduction

The lungs are often affected in connective tissue diseases (CTDs), with a variable degree of severity and protean clinical presentations by virtue of the complex anatomo-functional characteristics of the respiratory apparatus. Among the CTDs, systemic sclerosis (SSc) has the highest prevalence of clinically overt pulmonary involvement with a prevalence ranging between 70% and 90% of cases;¹ similarly, in idiopathic inflammatory myopathies, and in particular anti-synthetase syndrome, the prevalence is remarkable.² In systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS), pulmonary involvement has been reported with a variable prevalence according to the diagnostic method and criteria used.^3–8 In SLE and pSS, the immune-inflammatory process may affect not only the lung parenchyma but also pleural layers, respiratory muscles, and the pulmonary vascular system with different pathogenetic mechanisms. This often requires a comprehensive clinical and laboratory evaluation and a multi-disciplinary management to correctly characterize the extension of the organ impairment and to provide the best management. Besides, it is important to remind that the respiratory abnormalities may additionally be due to complications associated with the immunosuppressive therapy such as pulmonary drug-related toxicity^9,10 or, more frequently, recurrent infections. In pSS, they may also derive from a malignant evolution of an underlying lymphoproliferative disorder.

In this review, we provide an overview on the diagnosis and management of pulmonary manifestations in patients with SLE and pSS with the aim of raising the awareness of lung involvement among physicians taking care of SLE and pSS patients.

Search strategy

A narrative literature search was conducted to address research questions related to pulmonary manifestations in SLE and pSS patients. We considered different databases such as PubMed, Google Scholar, and Cochrane Library searching for case series, case reports, clinical trials, and review articles on lung involvement in SLE and pSS. Additional references were identified by searching the bibliographies of retrieved articles. We performed a keyword search restricted to the title of the articles, using terms relating to SLE, pSS, lung involvement, and treatment of lung involvement in CTDs. The date of publication was not used as an entry selection criterion. Articles were reviewed according to the article title and abstract, with all article types taken into consideration if they provided data relevant to the research questions.

Pulmonary involvement in SLE

SLE is a chronic autoimmune multi-systemic disease with a complex and multi-factorial pathogenesis, mostly affecting young women and characterized by a relapsing-remitting course. Organ involvement can be highly heterogeneous, and the respiratory system, along with skin, kidney, joints, and blood system, is frequently affected.^3,4

Pleuritis is definitely the most common manifestation, but other different vascular and parenchymal abnormalities have been reported (Table 1). The prognosis greatly varies according to the type of manifestation and on the response to the currently available therapies.

Table 1.

Lung involvement in SLE.

Type of lung involvement	Main clinical features
Lupus pleuritis	Chest, fever, cough, and dyspnea. Lupus pleuritis is often bilateral, exudative, and commonly of small/moderate entity
Parenchymal disease and airways disorders
Acute lupus pneumonitis (ALP)	Rapid-onset pneumonia with severe respiratory illness (dyspnea, tachypnea, and hypoxiemia), fever, cough, and basilar crackles. HRCT shows patchy bilateral consolidation or ground glass opacities, frequently in conjunction with pleural effusion
Diffuse alveolar hemorrhage (DAH)	Acute or subacute dyspnea, cough, and hemoptysis. Alveolar patchy or diffuse opacities on chest radiography. The DLCO is typically increased because of extravascular hemoglobin within the alveoli. Bronchoscopy with BAL is stained with blood
Systemic lupus erythematosus–associated interstitial lung disease (SLE-ILD)	Decreased exercise tolerance, non-productive cough, dyspnea, and basilar crackles at physical examination. The most common radiologic pattern is NSIP while UIP and BOOP are unusual. PFTs are characterized by a restrictive pattern and a decreased DLCO
Pulmonary venous thromboembolism	They are characterized by a lack of overt clinical symptoms in the early phase and by exertional dyspnea in a more advanced disease. Physical examination could reveal a loud second pulmonary heart sound. PFTs commonly show normal lung volumes with a reduction in DLCO. Transthoracic Doppler echocardiography can be useful for screening for PAH; however, RHC is required for definitive diagnosis and to orient between PAH different etiologies
Pulmonary arterial hypertension (PAH)
Neuromuscular disease with secondary pulmonary involvement	Dyspnea and/or chest pain, reduced lung volumes on PFTs, and diaphragm elevation on X-ray
Lung infections	They should always be excluded in patients with respiratory symptoms such as cough, fever, and dyspnea, especially in those taking immunosuppressive therapy. Chest radiograph and HRCT might show a picture indistinguishable from ALP, DAH, or ILD. Microbiological exams on serum, sputum, and BAL are therefore necessary to confirm the diagnosis

BAL, bronchioalveolar lavage; BOOP, bronchiolitis obliterans organizing pneumonia; DLCO, diffuse lung CO; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; NSIP, non-specific interstitial pneumonia; PFT, pulmonary function test; RHC, right heart catheterization; SLE, systemic lupus erythematosus; UIP, usual interstitial pneumonia.

Pleuritis

Pleural involvement is the most common pleuro-pulmonary manifestation of SLE. Pleuritis, with or without pleural effusions, has been reported in up to 50% of SLE patients during the disease course¹¹ and in as many as 93% of autopsy series.¹² Noteworthy, it is the only pulmonary manifestation which has been included in the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE.¹³ Long-standing disease, chronic damage, late-onset SLE, and positive anti-RNP and anti-Smith antibodies are associated with a nearly two-fold increased risk of developing pleuritis.¹⁴ It occurs with chest pain in up to 45% to 60% of patients,^3,15 but it can be asymptomatic and fortuitously diagnosed in routine radiographs performed for other reasons. Patients may also report fever, cough, and dyspnea.¹⁶ Pleural effusions in SLE are often bilateral, exudative, and commonly of small entity, but may occasionally be massive.¹⁷ Fibrothorax is a rare but potentially fatal complication of lupus pleuritis, which may require pleural decortication.¹⁸ The differential diagnosis mainly includes infections,¹⁹ pulmonary embolism (PE), malignancy, and congestive heart failure. When infections are excluded, high levels of C-reactive protein (CRP) in SLE patients have been associated with pleural disease or other forms of serositis during disease exacerbations.^20,21 Pleural involvement is commonly observed in patients with active SLE in other organs and systems.²⁰ Pleural fluid analysis does not provide any specific feature; however, it can be used to rule out other conditions.²² The fluid appearance can vary from clear, serous to bloody; physico-chemical analysis can reveal predominant polymorphonuclear cell, low glucose levels, and high levels of lactate dehydrogenase (LDH). Low complement levels and positive antinuclear antibodies (ANAs) can also be found in pleural fluid. Nonetheless, the detection of positive ANA should be interpreted with caution because a titre of ANA above 1:160 by indirect immunofluorescence has also been reported in malignant diseases.²³ Thoracoscopy may detect nodules on the visceral pleura histologically characterized by deposits of immune complexes (ICs) by immunofluorescence.²⁴ Treatment is mainly based on non-steroidal anti-inflammatory drugs (NSAIDs) or systemic glucocorticoids (GCs). The latters are commonly used in case of unresponsiveness to NSAIDs and/or in moderate-severe forms. In refractory cases, immunosuppressive drugs such as azathioprine (AZA), mycophenolate mofetil (MMF),²⁵ and methotrexate (MTX) are recommended. Finally, the anti-BlyS monoclonal antibody belimumab resulted to be effective in some cases.^26–31

Parenchimal disease

Acute lupus pneumonitis

Acute lupus pneumonitis (ALP) is a rare and severe manifestation of SLE affecting 1% to 4% of patients. In some series, it is reported as the initial disease presentation in up to half cases.³² ALP is more likely to occur during SLE flares, with multi-systemic involvement, including lupus nephritis; furthermore, anti-Ro/SSA antibodies have been associated with an increased risk of ALP.³³ In one series of 12 patients with ALP, the mortality rate was 50%, which derived from respiratory failure, infections, and thromboembolic events; among the survivors, up to one third developed chronic interstitial lung disease (ILD).³² The clinical picture of ALP is not specific and is usually characterized by a rapid-onset severe respiratory illness, fever, cough, and dyspnea. Physical examination typically shows tachycardia, tachypnea, hypoxemia, and basilar crackles. Chest radiographs are characterized by bilateral, acinar infiltrates in the lower lobes, while high-resolution computed tomography (HRCT) shows patchy consolidation or ground glass opacities, frequently in conjunction with pleural effusion.³⁴ Histopathologic findings include diffuse alveolar damage, hyaline membranes, and inflammatory cells infiltrates. By immunofluorescence, granular deposits of IgG and C3 can be found within the alveolar septa.^35,36

As clinical manifestations of ALP are non-specific, diagnosis can be very challenging. Viral, bacterial, and fungal infections need to be ruled out, especially the opportunistic ones if the patient is immunocompromised. Notably, in the current times, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia should be excluded as well.^37,38 Other alternative diagnoses include organizing pneumonia (OP), PE, drug toxicity, diffuse alveolar hemorrhage (DAH) and malignancy. If clinical or microbiological tests are non-diagnostic, lung biopsy is recommended to confirm the diagnosis. No controlled trials have been carried out for the treatment of lupus pneumonitis and the therapeutic recommendations mainly derive from case reports and clinical practice. Broad spectrum antibiotics, including those covering encapsulated organisms, should be administrated in all patients while awaiting microbiological results. The cornerstone of treatment is represented by systemic prednisone at the dose of 1 mg/kg/day. If no response is obtained within 72 hours, intravenous (IV) pulses of GCs (i.e. 1 g of methylprednisolone per day for three consecutive days) should be administered. Steroid-sparing immunosuppressive agents, such as AZA, MMF, or cyclophosphamide (CYC), should be concomitantly started. Intravenous immunoglobulins (IVIGs) and plasmapheresis may be useful in refractory cases.³³

DAH

DAH is an uncommon but potentially fatal manifestation of SLE, occurring in less than 2% of patients,³⁹ in most cases during the disease course rather than at the time of the diagnosis.⁴⁰ Despite aggressive immunosuppressive therapy, the mortality rate from DAH is still high, mainly for its rapid onset and fast progression over a few days.³³ DAH is most commonly reported in young women, especially in the setting of a serologically and clinically active disease.^41,42 The most relevant risk factor associated with the development of DAH is active renal disease, especially class III or IV lupus nephritis.^41–44 Furthermore, a recent case-control study reported that anti-Ro/SSA antibodies, thrombocytopenia, and elevated CRP may significantly be associated with lupus DAH.⁴⁵ Antiphospholipid antibodies (aPL) are also supposed to be contributory in some patients.⁴⁶ DAH is characterized by acute or subacute dyspnea, cough, and hemoptysis in the setting of a drop in blood hemoglobin level and bilateral alveolar opacities, patchy, or diffuse, on chest radiography. The diffusing capacity for carbon monoxide (DLCO) is typically increased because of the presence of extravascular hemoglobin within the alveoli. Bronchoscopy with bronchoalveolar lavage (BAL) is commonly performed in order to confirm DAH and to rule out infections and malignancies. BAL fluid is invariably stained with blood and does not clear with continuous lavage. Hemosiderin-laden macrophages in BAL fluid are an additional common finding. The two most frequent histologic patterns described in lupus DAH include bland pulmonary hemorrhage and vasculitis of the small arterioles.^41,47 Bland pulmonary hemorrhage has been suggested to be the most common cause of DAH in some series.⁴⁸ It is commonly associated with a predominant monocyte infiltration in the alveolar wall and arterial IC deposition.⁴⁸ Inflammation and necrosis of the alveolar and capillaries with a predominant pericapillary neutrophil infiltration are instead the common features of the inflammatory vasculitic pattern.⁴⁹ Since DAH may be life threatening, most patients are treated with a high dose of systemic GCs, especially IV pulses of methylprednisolone (Figure 1(a) and (b)). Some studies reported a better survival rate in patients receiving a higher dose of methylprednisolone than that conventionally used (4–8 g instead of 3 g).⁵⁰ Administration of CYC has demonstrated to improve survival,⁵¹ also in the most severe cases requiring mechanical ventilation;⁴¹ the combination of methylprednisolone and CYC is associated with an even increased survival rate.⁵² Plasma exchange and IVIG are considered rescue therapies for refractory disease, although supportive data are limited.⁴⁸ The anti-CD20 monoclonal antibody rituximab (RTX), in addition to GCs, has proven to be effective in case reports or in registries;⁵³ however, if the clinical picture is from mild to moderate, MMF or AZA may be reasonably used.^54,55

Figure 1.

Areas of bilateral parenchymal consolidations with a peribronchovascular distribution localized in the inferior lobes on high-resolution computed tomography (a) and the corresponding chest radiography image (b) in a patient with organizing pneumonia in systemic lupus erythematosus.

SLE-associated ILD

Chronic systemic lupus erythematosus–associated interstitial lung disease (SLE-ILD) is a rare manifestation of the disease, which affects up to 9% of patients.^3,56–58 SLE-ILD can occur after one or more episodes of ALP or in a more insidious fashion.³² Although no clinical or serologic markers have strongly been associated with the development of chronic SLE-ILD,⁵⁹ a recent systematic review demonstrated a potential association with late-onset disease.^60,61 Non-specific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), OP, lymphocytic interstitial pneumonia (LIP), follicular bronchiolitis, and nodular lymphoid hyperplasia have all been reported in association with SLE.⁶² NSIP is the most common radiologic pattern,⁵⁸ while UIP and OP are fairly unusual^62,63 (Figure 2(a) and (b)). SLE-ILD commonly occurs with a decreased exercise tolerance, non-productive cough, dyspnea, and basilar crackles at physical examination.⁶⁴ The diagnosis is often based on clinical and radiological findings, but it is crucial to rule out other possible causes of respiratory symptoms, such as infections, malignancy, and congestive heart failure. Pulmonary function tests (PFTs) are characterized by a restrictive pattern, defined by a decrease in forced vital capacity (FVC), total lung capacity, and DLCO. Chest radiographs may show the presence of ILD, but HRCT is the milestone for confirming lung interstitial involvement and for defining its radiologic pattern, which in turn correlates with a specific histopathologic diagnosis.

Figure 2.

Diffuse ground glass opacities, air-bronchogram images, and bilateral pleural effusion on high-resolution computed tomography in a patient with hemorragic alveolitis in systemic lupus erythematosus before (a) and after (b) methylprednisolone pulses and high-dose intravenous glucocorticoid therapy.

In recent years, novel serum biomarkers have been tested for evaluating ILD in SLE and other CTDs.⁶⁵ Among them it has to be mentioned Krebs von den Lungen-6 (KL-6), surfactant protein-A (SP-A), surfactant protein-D (SP-D), CC-chemokine ligand 18 (CCL18), and matrix metalloproteinase 7 (MMP7). In the future, they may be used for diagnosis, assessing the severity of disease, prediction of progression, and treatment responses in CTDs-ILD.⁶⁵

There are no definite guidelines for the management of SLE-ILD, and the therapeutic approach depends on the type, severity, and rate of progression of lung involvement. Patients with fibrotic ILD are less likely to benefit from anti-inflammatory or immunosuppressive therapy, while they may take advantage from the use of antifibrotic agents. A recent clinical trial in patients with progressive fibrosing ILDs of different etiologies, including autoimmune diseases, showed a decrease in the rate of decline of lung function with the use of the antifibrotic agent nintedanib.^66,67 With exception of fibrosing forms, the mainstay of therapy is high-dose prednisone (1 mg/kg/day) followed by gradual tapering. In a case series,⁵⁸ the treatment with prednisone was associated with an improvement of respiratory symptoms and DLCO in the majority of patients. Steroid-sparing agents commonly used for the treatment of ILD in CTDs include AZA, MMF, RTX, and CYC. However, data on the use of immunosuppressive drugs in SLE-ILD are insubstantial.^68–70 For patients affected with mild to moderate forms, AZA or MMF may be considered, while in the severe or rapidly progressive cases, CYC or RTX should be preferred. In the setting of a severe ILD flare, characterized by hypoxemia and marked impairment by PFTs, high dose of systemic GCs (i.e. methylprednisolone 1 g for 3 days) should be administered, in association with RTX or CYC, switching to another immunosuppressive agent such as AZA or MMF for maintenance therapy.⁷⁰

Pulmonary thromboembolic disease

Notably, SLE patients have an increased risk of developing venous thromboembolic events in the pulmonary circulation.^71,72 Yusuf et al.⁷¹ found that among hospitalized patients the risk of pulmonary venous thromboembolism (VTE) is higher in SLE patients compared to those without autoimmune diseases. Membranous nephropathy and aPL positivity are well-established risk factors for VTE, in particular the presence of aPL carries a six-fold increased risk of VTE.⁷³ Indeed, thrombotic events frequently occur in the setting of antiphospholipid antibody syndrome (APS), whose prevalence in SLE is estimated to be around 30%.^74–76 Noteworthy, recurrent episodes of VTE may lead to chronic thromboembolic pulmonary disease and, eventually, pulmonary arterial hypertension (PAH). Therapy of pulmonary thromboembolism is mainly based on anti-coagulants. Initial management does not differ if the patient is aPL positive or negative.³³

PAH

PAH is a rare and life-threatening pulmonary manifestation of SLE, much more frequent in SSc or mixed connective tissue disease (MCTD).⁷⁷ It is defined, on right heart catheterization (RHC), by a mean pulmonary artery pressure greater than 25 mmHg at rest and a normal pulmonary capillary wedge pressure when classified as pre-capillary.⁷⁸ Pulmonary hypertension can be secondary to a variety of diseases, such as ILD leading to hypoxemia, thromboembolic disease, pulmonary veno-occlusive disease (PVOD),⁷⁹ left-heart-sided valvulopathies, and sleep apnea disorder. On this regard, the World Health Organization has proposed a classification of the different forms of pulmonary hypertension into five groups based on the underlying cause.⁸⁰ In a cross-sectional study of 283 patients with SLE, pulmonary hypertension was observed in 4% of patients, based on Doppler echocardiography, while severe PAH (pulmonary systolic pressure by echocardiography >40 mmHg) was noted in about 1%.⁸¹ In most cases, SLE diagnosis precedes the detection of PAH but its early prevalence may be underestimated due to the lack of overt clinical symptoms in the early phase.⁸² The strongest association of PAH in the setting of SLE is with Raynaud’s phenomenon (RP), occurring in up to 60% of cases.⁸³ Other reported associations are with positive rheumatoid factor (RF), anti-ribonucleoprotein (RNP) antibodies, and serum endothelin-1 levels.^84,85 The clinical picture of PAH is characterized by exertional dyspnea, fatigue, non-productive cough, and, in advanced disease, symptoms of cor pulmonale. Physical examination findings commonly include a loud second pulmonary heart sound and a left parasternal lift. A chest radiography can show cardiomegaly and a pronounced pulmonary artery segment. PFTs in PAH commonly show normal lung volumes with a decrease in DLCO. The six-minute walk distance (6MWD) is reduced, in association with oxygen desaturation ⩾5%, often with an inflated heart rate response.⁸⁶ When PAH is caused by advanced ILD, lung volumes will show a restrictive pattern. Transthoracic Doppler echocardiography can be useful for PAH screening because it allows to estimate pulmonary artery pressures and right atrial and right ventricular size and function.⁸¹ However, RHC is required for a definitive diagnosis. Common histological findings in SLE-related PAH are represented by thickening of the arterial media and subintima in addition with angiomatoid lesions of the pulmonary muscular arteries and IC deposition in the arterial wall.^87,88 Rare cases of pulmonary vasculitis have been reported.⁸⁹ The management of SLE-associated PAH is similar to that of other CTDs or the idiopathic form.⁹⁰ General measures for patients affected with PAH may include oxygen, exercise, and diuretics. The main pharmacological approach is based on endothelin receptor antagonists, phosphodiesterase type-5 inhibitors (PDE5 inhibitors), and vasodilators. Monotherapy with a single-class agent can be administered, although the combination of oral drugs belonging to different classes is preferred in clinical practice to obtain a synergic effect and, at the same time, to reduce the risk of adverse effects by administering lower doses of each drug. Among the endothelin receptor antagonists used for PAH, there are the non-selective agents, bosentan, and macitentan, and the selective agent ambrisentan. Sildenafil, tadalafil, and vardenafil are PDE5 inhibitors with vasodilatory effects. A study examining the effect of oral sildenafil in 19 patients with SLE-associated PAH found that sildenafil-treated patients had a mean increase in 6MWD of 42 meters compared with a decrease of 13 meters in the placebo group after 12 weeks of treatment.⁹¹ The combination of ambrisentan and tadalafil has been associated with a significant decrease in the rate of clinical failure compared to monotherapy with either drugs alone.⁹² Data on the use of immunosuppressive therapy in SLE-associated PAH are inconclusive, but those patients with PAH secondary to ILD or pulmonary vasculitis may benefit from immunosuppressive agents.⁹³ In this regard, single studies reported a successful treatment of PAH with CYC⁹⁴ or RTX⁹⁵ but randomized clinical trials are needed to confirm these findings.⁹⁶

Shrinking lung syndrome

Shrinking lung syndrome (SLS) is an uncommon but well-recognized complication of SLE and other autoimmune diseases⁹⁷ such as SSc, pSS, and rheumatoid arthritis (RA).⁹⁸ SLS affects from 0.5% to 1.53% of all lupus patients,⁹⁹ in most cases 4 to 5 years after the initial diagnosis.¹⁰⁰ Pleural involvement, positive anti-double-stranded-DNA (dsDNA), and anti-RNP antibodies are associated with the development of SLS.¹⁰¹ Different etiologies have been proposed, but the precise pathophysiological mechanism has yet to be demonstrated.¹⁰² It is possible that myopathy or myositis of the diaphragms may lead to muscular disfunction;¹⁰³ however, this hypothesis is in contrast with some reports suggesting a normal diaphragm function in most patients with SLS.¹⁰⁴ Another hypothesis postulates a phrenic nerve damage or paralysis.^105,106 Some other reports suggest a possible role of chronic pleural inflammation leading to lung hypo-inflation and altered lung compliance.^107,108 SLS commonly occurs with dyspnea and/or chest pain, reduced lung volumes by PFTs, and diaphragm elevation by X-ray. For establishing the diagnosis of SLS parenchymal diseases, infections and PE need to be excluded. GC therapy and immunosuppressants are reported to improve both pulmonary function and symptoms.^108–110 RTX and CYC have been successfully used for the treatment of SLS,^111–113 while the efficacy of theophylline or other beta-adrenergic agonists is still controversial.¹¹⁴ Finally, physiotherapy for pulmonary rehabilitation may also be helpful.¹⁰³

Lung infections

Lung infections can be considered one of the most relevant causes of morbidity and mortality among hospitalized patients affected with SLE¹¹⁵ and one of the most common causes of lung involvement in SLE patients. High disease activity, disease duration, and use of immunosuppressants are recognized risk factors for the development of lung infections.¹¹⁶ Furthermore, a mean daily dose of 15 mg of prednisolone at the onset of pneumonia is reported to be an adjunctive threatening of death.¹¹⁷ Deficiencies in the complement system, impaired chemotaxis and phagocytosis of macrophages, and homozygosity for mannose-binding lectin variant polymorphisms put SLE patients at high risk for a variety of bacterial (especially encapsulated organisms) and opportunistic lung infections.^117–119 Nevertheless, functional asplenia, which is reported in up to 5% of SLE patients, may also play a role.¹²⁰ The most common causes of lung infection in a Canadian study were P. aeruginosa, H. influenzae, S. marcescens, K. pneumoniae, and Legionella species;¹²¹ other potential causes include Cytomegalovirus, disseminated Herpes simplex, and Pneumocystis jirovecii.^122,123 According to EULAR recommendations, vaccination against pneumococcal disease and influenza should be strongly encouraged for most people with SLE and other autoimmune rheumatic diseases.¹²⁴

Pulmonary involvement in pSS

pSS is defined as an autoimmune epithelitis specifically characterized by impairment of exocrine glands (mainly lacrimal and salivary) due to inflammatory infiltrate.¹²⁵ It also shows extra-glandular, multi-organ involvement^126,127 and respiratory manifestations (Table 2) are among the most prevalent extra-glandular complications affecting 9% to 75% of patients¹²⁸ according to the detection methods and patient selection criteria.^129–131 Upper airway disorders with dryness in nasal and oropharyngeal mucosa are definitely among the most frequent manifestations and are due to mucosal dryness, mucus viscosity disorders, and impaired mucociliary clearance caused by the long-standing inflammation that finally leads to atrophy of the submucosal glands of the airway mucosa.¹³² Chronic obstructive pulmonary disease^133–136 and bronchial hyperresponsiveness^137,138 have also an increased prevalence in pSS patients in respect to general population. Respiratory and lung involvement have proven to significantly decrease the quality of life and are associated with increased mortality.^8,139

Table 2.

Lung involvement in pSS.

Type of lung involvement	Main clinical features
Airways disorders
Upper airways inflammation	Dryness in nasal and oropharyngeal mucosa finally leading to atrophy of the submucosal glands of the airway mucosa
Chronic obstructive pulmonary disease and reactive airway disease	Shortness of breath, chronic dry cough, or wheezing due to airway hyperresponsiveness. PFTs allow the distinction of the two patterns
Bronchiolitis (follicular bronchiolitis, chronic bronchiolitis, and bronchiolitis obliterans)	It traditionally presents with cough and dyspnea. PFT findings may be normal or show either a restrictive or obstructive pattern. It appears as a reticular or reticulonodular pattern on HRCT
Bronchiectasis	Dry cough, isolated dyspnea, and hemoptysis in rare occasions. Patients with bronchiectasis have a higher frequency of respiratory infections and pneumonia
Parenchymal disease
Interstitial lung disease	Non-productive cough and dyspnea are present in half of patients, the remaining are completely asymptomatic. On auscultation, it is characterized by fine bibasilar end-inspiratory “velcro-like” crackles. The most common ILD pattern is NSIP, followed by UIP, OP, and LIP. In early involvement, it is easy to observe a reduction of DLCO (alveolar inflammation) with a preserved FVC (normal lung volumes)
Lymphoma and pseudolymphoma	Cough, slowly progressive dyspnea, and traditional B symptoms (fever, night sweats, and weight loss) are characteristic of lung lymphoma. Parenchymal radiographic findings are often associated to mediastinal lymphadenopathy and pleural effusions Pseudolymphoma is generally asymptomatic, and it usually appears as a solitary nodule or mass
Pulmonary amyloidosis	Cough or dyspnea along with fatigue, weakness, hemoptysis, and pleuritic chest pain. Radiologically it is characterized by large, calcified, randomly distributed, irregular, smooth-bordered nodules alone, or in association with LIP
Sarcoidosis	Asymptomatic or presenting with exertional dyspnea or dry cough. Heerfordt’s syndrome is defined by the characteristic parotid enlargement and the presence of uveitis. Radiographic abnormalities include bilateral hilar lymphadenopathy, pulmonary infiltrates, or fibrosis
Cystic lung disease	Mostly subclinical. Cysts are usually bilateral with the majority located in the middle lung
Pulmonary venous thromboembolism	They are characterized by a lack of overt clinical symptoms in the early phase and by exertional dyspnea in a more advanced disease. Physical examination could reveal a loud second pulmonary heart sound. PFTs commonly show normal lung volumes with a reduction in DLCO. Transthoracic Doppler echocardiography can be useful for screening for PAH however, RHC is required for definitive diagnosis and to orient between PAH different etiologies
Pulmonary arterial hypertension (PAH)
Lymphocytic pleuritis	Rare manifestation in pSS characterized by chest, fever, cough, dyspnea, and exudative pleural effusion
Neuromuscular disease with secondary pulmonary involvement	Dyspnea, persistent episodes of chest pain, restrictive syndrome, and the absence of significant interstitial and/or pleural disease

DLCO, diffuse lung CO; FVC, forced vital capacity; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; LIP, lymphocytic interstitial pneumonia; NSIP, non-specific interstitial pneumonia; OP, organizing pneumonia; PAH, pulmonary arterial hypertension; PFT, pulmonary function test; pSS, primary Sjogren’s syndrome; RHC, right heart catheterization; UIP, usual interstitial pneumonia.

Airway disorders

Bronchiolitis

Bronchiolitis is the most frequent airway disease in pSS, and it is classified into three main types: follicular bronchiolitis, chronic bronchiolitis, and bronchiolitis obliterans. Lung biopsy–proven prevalence reaches 12% of cases (29% of patients have histopathologic changes consistent with follicular bronchiolitis, 21% with chronic bronchiolitis, and 7% with bronchiolitis obliterans), but frequency increases to 29% with HRCT evaluation.¹⁴⁰ It traditionally occurs with cough and dyspnea, which may be the first manifestation of pSS in up to 36% of patients.¹⁴¹ The course of bronchiolitis in pSS is typically fairly mild; however, severe cases have been reported.^141,142 Follicular bronchiolitis has been specifically linked to CTDs, such as pSS and RA. It traditionally occurs with cough and dyspnea, even without objective clinical signs of lung involvement. PFT findings may be normal or show either a restrictive or obstructive pattern. Radiographically, it appears as a reticular or reticulonodular pattern on HRCT¹⁴³ (Figure 3(a) and (b)), while histopathologically, it is characterized by the presence of hyperplastic lymphoid follicles with reactive germinal centers distributed along bronchovascular bundles.¹⁴⁴ Bronchiolitis obliterans is defined by a mosaic pattern with air trapping on HRCT.¹⁴² Chronic bronchiolitis and bronchiolitis obliterans present with a spectrum of histological changes such as lymphocytic infiltration of small airways, bronchiolar smooth muscle hypertrophy, obstruction of bronchioles with mucus or even complete obliteration of bronchioles with scarring; these aspects are often indistinguishable from other etiologies.¹³⁹ There are scant data on the effect of therapy on bronchiolitis in pSS. Macrolides (most commonly azithromycin 250 mg 3 days a week for 2–3 months¹⁴⁵), inhaled GCs and inhaled bronchodilators may strongly improve the respiratory status of patients.¹⁴⁶ GCs and RTX could be an option for follicular bronchiolitis^147–149 while a combination of hydroxychloroquine and MMF had been administered to patients with constrictive bronchiolitis showing stability or slight improvement of respiratory function.¹⁴²

Figure 3.

Reticular pattern during inspiration (a) and expiration (b) on high-resolution computed tomography in a patient affected with follicular bronchiolitis in primary Sjögren’s syndrome.

Bronchiectasis

Radiographically evident bronchiectasis has been described in 23% to 54% of patients with pSS.^150,151 Patients with bronchiectasis tend to be older at pSS diagnosis, have a higher frequency of hiatal hernia and a lower prevalence of anti-Ro/SSA antibodies but increased presence of anti-smooth muscle cell antibodies.¹⁵² Most patients usually show cylindrical shape bronchiectasis and have lower lobe–predominant disease.¹⁵² Clinical symptoms are variable and non-specific: dry cough, isolated dyspnea, and hemoptysis in rare occasions. In addition, patients with bronchiectasis have a higher frequency of respiratory infections (56% vs 3%) and pneumonia (29% vs 3%).¹⁵² Treatment is based on strategies to relief from secretions¹⁴⁵ like mucolytic agents and expectorants, nebulized saline or hypertonic saline, oscillatory positive expiratory pressure, postural drainage, and mechanical high-frequency chest wall oscillation therapies. Chronic administration of macrolides in patients without non-tuberculous mycobacterium colonization or infection is also advisable.¹⁴⁵

Parenchymal involvement

Interstitial lung disease (pSS-ILD)

ILD prevalence among pSS patients is around 20% when defined by HRCT or reduced FVC and/or DLCO. Besides HRCT, which is the gold standard, quantitative CT (QCT) analysis may be a promising tool to assess pSS-ILD and its severity. It is based on software providing highly accurate and operator-independent measurements, termed QCT indices, which have been rapidly validated in systemic autoimmune diseases. Quantitative lung assessment methods are capable of distinguishing limited ILD from extensive ILD, which is responsible for poor prognosis in pSS.¹⁵³ ILD prevalence increases along with the disease duration (10% after 1 year from diagnosis, up to 47% after 15 years of disease) but in 10% to 51% of patients, it occurs years before pSS onset.¹⁵⁴

Symptoms as non-productive cough and dyspnea are observed in 40% to 66% of patients but are not specific; 24% to 48% of patients are completely asymptomatic.^154,155 Physical examination is often unremarkable but fine bibasilar end-inspiratory “velcro-like” crackles at auscultation may lead to ILD suspicion.¹⁵⁶ Digital clubbing, weight loss, focus score ⩾4 in minor salivary gland biopsy, lower albumin-to-globulin ratio, higher levels of IgM, LDH, Erythrocyte Sedimentation Rate (ESR), and positive anti-Ro52 antibodies are frequently found in pSS-ILD patients.^157,158 Older age, smoking, increased ANA titer and CRP level, and RF have been reported as potential risk factors for the development of ILD.¹⁵⁷ Patients with non-sicca-onset pSS-ILD less commonly have hypergammaglobulinemia, increased RF or positive anti-SSA, and anti-SSB antibodies compared with patients with sicca-onset pSS-ILD,¹⁵⁹ making ILD recognition challenging. In a patient with pSS and suspected ILD, an oximetry testing is part of the patient’s initial evaluation; further investigations include HRCT with expiratory views and PFTs with DLCO measurement which should be performed and followed initially at 3- to 6-month intervals for at least 1 year because of variable natural history of the disease progression.¹⁴⁵ Discordance between baseline PFT abnormalities, degree of symptoms, and HRCT findings can be observed:¹⁶⁰ the incidence of parenchymal HRCT changes appear to be earlier and greater in frequency than what clinical symptoms would indicate; moreover, HRCT findings are not always accompanied by substantial alterations in PFTs.¹⁶⁰ In early involvement, it is easy to observe a decrease in DLCO with a preserved FVC because inflammation, affecting the alveolar membrane, causes an impairment of gas-exchange function with preserved lung volumes.¹⁵⁴ Therefore, DLCO is highly sensitive to predict the presence of ILD while FVC is more useful for assessing the disease extent.¹⁶¹ A novel non-invasive tool based on lung ultrasound examination could be helpful for screening of pSS-ILD involvement¹⁵⁴ because plain chest radiographs are insufficient to detect early abnormalities.¹⁶⁰ Imaging features of pSS-ILD are complex and include variable combination of ground glass opacities, reticular abnormalities, consolidation, honeycombing, cysts, nodules, and also bronchiectasis.¹⁴⁰ Surgical lung biopsy is not routinely recommended but may be considered in neoplastic and non-neoplastic lymphoproliferative disorder for ruling out cancers, amyloidosis, suspected infection failing empiric therapies, and when less invasive testing is not diagnostic.¹⁴⁵ Notably, there are cases of lymphoma and amyloidosis presenting with a radiographic pattern similar to LIP; thus, tissue biopsy is essential to ascertain a LIP diagnosis.^162–164 The most common ILD pattern is NSIP, found in 41% to 45% of pSS-ILD patients,¹⁶² followed by UIP in 10%, OP in 4%, and LIP which has been classically linked to pSS and occurring in 4% to 9% of cases.^156,158 The remaining have combined HRCT patterns.¹⁵⁸ Guidelines for evaluation and management of pulmonary disease in pSS have recently been published.¹⁴⁵ No standard definition exists for staging, but EULAR Sjogren’s syndrome disease activity index (ESSDAI), imaging, and PFTs could drive the initiation of therapy.¹⁶⁵ No treatment or serial observations is suggested for mild disease activity; for moderate-severe disease activity, oral corticosteroids plus MMF, or AZA as first-line GCs-sparing or as adjunctive agents is recommended.¹⁶⁵ If there is no satisfactory response, it is advisable to perform a critical review of HRCT to determine whether the primary pattern is fibrotic or inflammatory; in the latter case, RTX, calcineurin inhibitors, tacrolimus over cyclosporine A (CsA), or CYC are available options.¹⁴⁵ For progressive fibrotic ILD, it is possible to consider an antifibrotic therapy, such as nintedanib, which is approved by the Food and Drug Administration (FDA) for progressive fibrotic lung disease in SSc.¹⁴⁵ More specifically, NSIP pattern shows good response to GCs (0.5–1 mg/kg/day tapered over months to 5–7.5mg/day) associated with other drugs as AZA or CYC¹⁴⁹ while UIP is considered as an irreversible lung disease with a high risk of progression despite immunosuppressive therapy.^162,166 In patients with OP, it is reported a good initial response to GC therapy using adjunctive immunosuppressive agents such as AZA, CsA, infliximab, RTX, and tocilizumab in refractory cases.^{140,165,167,168} LIP seems to be a reversible lung disease with a potential risk of progression through the development of honeycombing¹⁶⁴ although the majority of patients with LIP treated with GCs remain clinically stable or improve. Other immunosuppressive agents such as AZA or CYC have been used but with variable response¹⁶⁹ and RTX has been reported as effective.¹⁴⁹ Other experimental therapies are under study for pSS and may be of potential usefulness also for lung involvement in light of the common systemic immunological mechanisms underlying the disease. Belimumab could be an option in consideration of the critical role of B-cell activating factor (BAFF) and of B-cells in the pathogenesis of pSS. Moreover, the combination of RTX and belimumab, based on previous experience^26,170–172 is currently being explored for pSS and may be considered for patients with severe lung involvement;¹⁷³ belimumab given immediately before RTX should be useful against tissue lymphoid inflammation because the first drug, by depleting local BAFF, can facilitate the action of the second.¹⁷⁴

Ianalumab, an IgG1 monoclonal antibody against BAFF-R, is currently under study for salivary gland invovement.¹⁷⁵ Abatacept, a CTLA-4 monoclonal antibody that modulates T-cell co-stimulation, has been shown to give some benefit in pSS improving disease activity scores and reducing lymphocytic foci, local T-cells and gammaglobulins;¹⁷⁶ it might be also beneficial in pulmonary pSS. Iscalimab, a monoclonal antibody targeting CD40/CD40 L pathway which is key factor in the organization of the germinal centers, could become a viable option.¹⁷⁷ Direct inhibition of inflammatory cytokines may be of potential benefit in pulmonary pSS as well. Interleukin (IL)-17 has shown to play an important role in the pathogenesis of pSS because an increased number of IL-17 Ralfa-expressing T-cells have been found in minor salivary glands in pSS patients.¹⁷⁸ Type-I interferon has in turn a key role in pSS pathogenesis and could be a potential target in pulmonary pSS.^179–181 In addition, blocking downstream signaling of pro-inflammatory cytokines through use of Janus kinase (JAK) inhibitors may be effective as recent evidence suggests it may also influence BAFF signaling.¹⁸² There is some evidence on the efficacy of JAK inhibitors in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (IPF). It would be important to explore their role even in pulmonary pSS.^139,183,184 Data on prognosis of pSS-ILD are heterogeneous. Risk factors associated with death are decreased FVC and forced expiratory volume (FEV₁), severe lung involvement,¹⁸⁵ and higher number of reticulations on HRCT, number of lymphoblastic foci in biopsy, and high CO₂ arterial pressure.¹⁵⁴ By multivariate analysis, low O₂ arterial pressure, presence of microscopic honeycombing,¹⁴⁰ and severity of fibroblastic foci on surgical lung biopsy¹⁸⁶ seem to be independently associated with worse survival. Patients with pre-existing ILD are at risk of acute exacerbation.¹⁸⁷ UIP pattern is at higher risk for this complication¹⁸⁸ with a rate of mortality up to 50% at 3 months from onset.¹⁸⁹ Treatment of acute exacerbations is commonly based on high-dose GCs in monotherapy or in association with CYC, oral tacrolimus, or CsA usually along with broad spectrum antibiotic therapy because of the challenging differential diagnosis with bilateral pneumonia. Recently, reduction of acute exacerbations risk in IPF employing nintedanib has been reported.^156,190

Lymphoma and pseudolymphoma

Patients with pSS are at higher risk for developing non-Hodgkin lymphoma¹⁹¹ with a relative risk of 44.4^191,192 and a lifetime risk around 5% to 10%.⁶⁹ The mucosa-associated lymphoid tissue (MALT) lymphoma is the most common subtype,^193–195 secondary to lymphocytic infiltration of polyclonal B- and T-cells evolving into a monoclonal B-cell proliferation.^194,196 Well-known risk factors include purpura, parotid enlargement, hypocomplementemia, type-II cryoglobulinemia,^197–199 CD4 T-cell lymphopenia, and low CD4/CD8 ratio.^193,194 Lymphoma is more frequently described in salivary and lacrimal glands and in the lymph nodes. Pulmonary localization comprises 20% of all lymphomas in patients with pSS,¹⁴⁹ and it is usually a low-grade extra nodal marginal B-cell lymphoma of the MALT type.

However, even if it is not routinely searched, it may also originate from a salivary gland B-cell clone previously expanded in that microenvironment, and then further expanding and becoming malignant by a second trigger in the lung microenvironment.²⁰⁰

Symptoms generally include cough, slowly progressive dyspnea, and traditional B symptoms (fever, night sweats, and weight loss). Radiographic findings comprise solitary or multi-focal nodules or masses, bilateral alveolar infiltrates, interstitial opacities, airspace consolidation, or ground glass attenuation, all having been described with a mild predilection for the lower lobes.²⁰¹ Mediastinal lymphadenopathy and pleural effusions may accompany parenchymal abnormalities. Biopsy is necessary for definitive diagnosis^202,203 because HRCT features in MALT lymphoma can be indistinguishable from benign lymphoproliferative processes. The average 5-year survival rate is 65% to 90%²⁰⁴ and watchful waiting without specific treatment is reserved for asymptomatic cases. Treatment is indicated for patients with bulky lymphadenopathies and/or splenomegaly, risk of local compressive disease resulting in organ dysfunction, significant cytopenia from bone marrow compromise, and/or rapid disease progression.²⁰⁵ Overt lymphomas require specific hematological treatment based on RTX and chemotherapy regimens.^165,206

Pseudolymphoma, or pulmonary nodular lymphoid hyperplasia, is a localized lymphoproliferative non-malignant disease²⁰⁷ characterized by infiltration of mature polyclonal lymphocytes and plasma cells.¹⁶⁴ It is typically asymptomatic, although it can present with cough and dyspnea and is most commonly seen in patients with isolated sicca symptoms.¹³⁰ It generally appears as a solitary nodule or mass on HRCT.²⁰⁸ If mediastinal lymphadenopathy or the presence of pleural effusions is noted, a diagnosis of lymphoma should be considered, and histological confirmation is mandatory. Pseudolymphoma generally regresses after treatment with GCs or immunosuppressive therapy but rarely it progresses to lymphoma.^209,210

Pulmonary amyloidosis

Amyloidosis is a heterogeneous group of disorders associated with extracellular deposition of fibrillar plasma proteins²¹¹ whose type is determinant for clinical classification. Pulmonary involvement in pSS occurs in light-chain (AL) amyloidosis, whereas reactive (AA) and hereditary forms are uncommon. The two commonly seen patterns include nodular and septal amyloidosis. It is a rare complication of pSS,¹³⁰ and a literature review²¹² reports 37 cases identified with a median delay of 7 years from pSS diagnosis. Most patients are symptomatic presenting cough or dyspnea²¹² along with fatigue, weakness,²¹³ hemoptysis,²¹⁴ and pleuritic chest pain.²¹⁵ Identified associated abnormalities include immune thrombocytopenia,²¹⁶ cryoglobulinemia,²¹³ RP,¹³⁰ APS,²¹⁷ renal disease,²¹⁸ and lymphoma.^212,216 The most common form of pSS-related pulmonary amyloidosis is the localized nodular type;²¹² it usually occurs alone but may also be associated with pulmonary lymphoma,²¹⁹ reflecting the localized clonal proliferation of B-lymphocytes or plasma cells secreting light chains.²²⁰ Radiologically, it presents with large, calcified, randomly distributed, irregular, smooth-bordered nodules²²¹ alone or in association with LIP.^140,213,215 Surgical lung biopsy is generally required to establish the diagnosis.^212,222 The prognosis is unknown, and there are no data to support any definitive therapeutic option. Observation alone may be sufficient in patients with localized nodular amyloidosis. The efficacy of GCs is anecdotal, and the improvement observed may reflect a favorable response of the underlying NSIP or LIP to GCs therapy.²¹²

Cystic lung disease (CLD)

Lung cysts are defined by the presence of clearly demarcated airspaces surrounded by thin (<2 mm) walls. CLD has been noted in up to 20% patients with pSS, being mostly subclinical and with limited impact on outcome. Cysts are mostly bilateral with the majority located in the middle lung.^139,223 Association between anti-SSB/La antibodies and the presence of lung cysts has been reported:²²⁴ anti-SSB/La has a higher diagnostic specificity for pSS than does anti-SSA/Ro alone, supporting the fact that CLD is a specific feature of pSS even though the pathogenic role of anti-La/SSB antibodies remains to be determined.²²⁵ Lung cysts have been associated with LIP, amyloidosis, or MALT B-cell lymphoma. As lung cysts in pSS are not attributable to active disease, they do not require immunosuppressive therapy.²²⁵

Sarcoidosis

The prevalence of sarcoidosis in patients with pSS has been estimated at between 1% and 2%.^226,227 Parotid enlargement can be part of a rare sarcoid manifestation, called Heerfordt’s syndrome and characterized by the presence of facial nerve palsy, parotid gland enlargement, anterior uveitis, and low-grade fever. It is important to differentiate if sarcoidosis mimics or coexist with pSS even though making a differential diagnosis may be difficult due to similar clinical manifestations at onset including respiratory symptoms.²²⁸ Hence, it is necessary focusing on three specific aspects: the existence of extra-glandular features, the immunologic profile, and the histologic analysis of minor salivary glands.²²⁷

Recently, the ultrasound-guided parotid biopsy in pSS allows differentiation with sarcoidosis.²²⁹

The correct diagnosis has important therapeutic and prognostic implications: lung sarcoidosis frequently resolves spontaneously without significant residual functional impairment, whereas pSS pulmonary involvement frequently requires immunosuppressive treatment beyond GCs²²⁸ and often leads to permanent defects.

Pulmonary VET

Patients with pSS are thought to be at increased risk for deep vein thrombosis and PE with the highest risk during the first year after pSS diagnosis.^230,231 Inflammation can contribute to the development of VTE because it favors clotting, decreases the activity of natural anti-coagulant mechanisms, and impairs the fibrinolytic system. Thrombosis might be related also to the presence of antiphospholipid antibodies, being lupus anti-coagulant (LAC) an important marker for APS.²³² Treatment of PE is based on anticoagulation while the role of immunosuppressive therapy has yet to be established.

PAH

PAH is a rare but severe complication of pSS. Pre-capillary PAH is characterized by vascular proliferation and remodeling of the small pulmonary arteries resulting in a progressive increase in pulmonary vascular resistance and ultimately in right ventricular failure and death.²³³ PAH in pSS can also occur as a result of PVOD,²³⁴ valvular heart diseas,²³⁵ or ILD.²³³ The exact prevalence of PAH in pSS is unknown; one study reported echocardiographic evidence of PAH in 22% of patients,²³⁶ nevertheless RHC represents the gold standard for the diagnosis.²³⁷ In a recent Chinese case-control study with a cohort of 103 patients with pSS-PAH diagnosed by RHC,²³⁸ the 1-, 3-, and 5-year survival rates were 94.0%, 88.8%, and 79.0%, respectively; a low cardiac index and an increased damage index were significantly and independently associated with survival. The main symptom is exertional dyspnea²³³ which is very unspecific and sometime misleadingly associated to ILD. This determines a delay between dyspnea onset and PAH diagnosis greater than 1 year in 69% of patients.^233,239 pSS-PAH has worse hemodynamic profiles on RHC than SSc-PAH and SLE-PAH, probably because diagnosis is performed in a more advanced stage of the illness.²⁴⁰ Recognized associations with pSS-PAH include hypergammaglobulinemia, positive ANA, high RF level, anti-RNP antibodies, and RP.²⁴⁰ Histological examination of the lungs has shown intimal and medial hypertrophy associated with plexiform lesions in the pulmonary arteries, whereas vasculitis and inflammatory infiltrates are not usually observed.²⁴¹ However, an immunologic etiology is suggested by the presence of IC in the pulmonary vessel walls of pSS–PAH patients.²⁴¹ Treatment with PAH-targeted drugs (endothelin receptor antagonists, PDE5 inhibitors, and epoprostenol) is the backbone of therapy.²³³ The benefits of immunosuppressive agents such as CYC, MTX, leflunomide, tacrolimus, or AZA²³¹ plus GCs have been reported in several cases²⁴² but their effectiveness combined with PAH-target drugs requires further study.

Lymphocytic pleuritis

Pleural effusion has rarely been described in pSS.^243,244 The presence of a coexisting autoimmune disease, such as RA or SLE must be excluded.²⁴⁵ The pleural fluid is a lymphocytic-predominant exudate with increased levels of RF, anti-SSA, anti-SSB autoantibodies,²⁴⁵ and low levels of complement. Lymphocytic infiltration of the pleura was found on pleural biopsies.²⁰⁸ Controlling the systemic inflammation and use of steroid therapy is the mainstay of therapy.²⁴⁴

Neuromuscular diseases with secondary lung involvement

Neuromuscular diseases with secondary pulmonary involvement have also been described in pSS.^246–249 SLS, although traditionally associated with SLE, has been very rarely reported.²⁴⁶ Pathogenesis is still unknown: micro atelectasis and hyaline membranes caused by surfactant deficiency, diaphragmatic myopathy or phrenic nerve neuropathy have been proposed as putative hypothesis. It is commonly characterized by dyspnea, persistent episodes of chest pain, restrictive syndrome, and the absence of significant interstitial and/or pleural disease. In one case report, it has been successfully treated with RTX.²⁴⁶ Hypokalemic periodic paralysis associated with a distal renal tubular acidosis, which occurs in up to 5% of patients with pSS, can sufficiently severe to cause respiratory muscle weakness.²⁴⁷ Finally, lung involvement could be secondary to proximal skeletal myopathy;²⁴⁸ a case of pSS complicated with inflammatory myopathy and ILD responsive to corticosteroids therapy has been reported.²⁴⁹

Footnotes

Author contributions

Roberto Depascale and Giulia Del Frate equally contributed to this work.

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Andrea Doria

References

Zanatta

Codullo

Avouac

, et al. Systemic sclerosis: recent insight in clinical management. Joint Bone Spine 2020; 87: 293–299.

Gasparotto

Gatto

Saccon

, et al. Pulmonary involvement in antisynthetase syndrome. Curr Opin Rheumatol 2019; 31: 603–610.

Keane

Lynch

III . Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 2000; 55: 159–166.

Gatto

Zen

Ghirardello

, et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013; 12: 523–536.

Quadrelli

Alvarez

Arce

, et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus 2009; 18: 1053–1060.

Flament

Bigot

Chaigne

, et al. Pulmonary manifestations of Sjogren’s syndrome. Eur Respir Rev 2016; 25: 110–123.

Luppi

Sebastiani

Sverzellati

, et al. Lung complications of Sjogren syndrome. Eur Respir Rev 2020; 29: 200021.

Palm

Garen

Enger

. Clinical pulmonary involvement in primary Sjögren’s syndrome: prevalence, quality of life and mortality—a retrospective study based on registry data. Rheumatology 2013; 52: 173–179.

Malik

Myers

DeRemee

, et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996; 154: 1851–1856.

10.

Lateef

Shakoor

Balk

RA.

Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005; 4: 723–730.

11.

Orens

Martinez

Lynch

III . Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1994; 20: 159–193.

12.

Haupt

Moore

Hutchins

GM.

The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 1981; 71: 791–798.

13.

Fanouriakis

Kostopoulou

Alunno

, et al. Update 19 of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 736–745.

14.

Mittoo

Fell

Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 2014; 35: 249–254.

15.

Palavutitotai

Buppajarntham

Katchamart

Etiologies and outcomes of pleural effusions in patients with systemic lupus erythematosus. J Clin Rheumatol 2014; 20: 418–421.

16.

Hellman

Kirsch

Whiting-O’Keefe

, et al. Dyspnea in ambulatory patients with SLE: prevalence, severity, and correlation with incremental exercise testing. J Rheumatol 1995; 22: 455–461.

17.

Bouros

Panagou

Papandreou

, et al. Massive bilateral pleural effusion as the only first presentation of systemic lupus erythematosus. Respiration 1992; 59: 173–175.

18.

Sharma

Smith

Al-Hameed

Fibrothorax and severe lung restriction secondary to lupus pleuritis and its successful treatment by pleurectomy. Can Respir J 2002; 9: 335–337.

19.

Rojas-Serrano

Pedroza

Regalado

, et al. High prevalence of infections in patients with systemic lupus erythematosus and pulmonary hemorrhage. Lupus 2008; 17: 295–299.

20.

Man

Mok

CC.

Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus 2005; 14: 822–826.

21.

ter Borg

Horst

Limburg

, et al. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990; 17: 1642–1648.

22.

Good

Jr King

Antony

, et al. Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. Chest 1983; 84: 714–718.

23.

Porcel

Ordi-Ros

Esquerda

, et al. Antinuclear antibody testing in pleural fluid for the diagnosis of lupus pleuritis. Lupus 2007; 16: 25–27.

24.

Pandya

Agus

Grady

RF.

In vivo LE phenomenon in pleural fluid. Arthritis Rheum 1976; 19: 962–963.

25.

Iaccarino

Rampudda

Canova

, et al. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007; 6: 190–195.

26.

Depascale

Gatto

Zen

, et al. Belimumab: a step forward in the treatment of systemic lupus erythematosus. Expert Opin Biol Ther 2021; 21: 563–573.

27.

Iaccarino

Andreoli

Bocci

, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun 2018; 86: 1–8.

28.

Trentin

Gatto

Zen

, et al. Effectiveness, tolerability, and safety of belimumab in patients with refractory SLE: a review of observational clinical-practice-based studies. Clin Rev Allergy Immunol 2018; 54: 331–343.

29.

Doria

Stohl

Schwarting

, et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheum 2018; 70: 1256–1264.

30.

Gatto

Saccon

Zen

, et al. Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting. Arthritis Rheum 2020; 72: 1314–1324.

31.

Carrión-Barberà

Salman-Monte

Castell

, et al. Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab. Eur J Rheumatol 2019; 6: 150–152.

32.

Matthay

Schwarz

Petty

, et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine 1975; 54: 397–409.

33.

Tselios

Urowitz

MB.

Cardiovascular and pulmonary manifestations of systemic lupus erythematosus. Curr Rheumatol Rev 2017; 13: 206–218.

34.

Ahuja

Arora

Kanne

, et al. Imaging of pulmonary manifestations of connective tissue diseases. Radiol Clin North Am 2016; 54: 1015–1031.

35.

Swigris

Fischer

Gillis

, et al. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest 2008; 133: 271–280.

36.

Rodríguez-Iturbe

García

Rubio

, et al. Immunohistologic findings in the lung in systemic lupus erythematosus. Arch Pathol Lab Med 1977; 101: 342–344.

37.

Kichloo

Aljadah

Albosta

, et al. COVID-19 and acute lupus pneumonitis: diagnostic and treatment dilemma. J Investig Med High Impact Case Rep 2020; 8: 2324709620933438.

38.

Zen

Fuzzi

Astorri

, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun 2020; 112: 102502.

39.

Badsha

Teh

Kong

, et al. Pulmonary hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 2004; 33: 414–421.

40.

Andrade

Mendonca

Farinha

, et al. Alveolar hemorrhage in systemic lupus erythematosus: a cohort review. Lupus 2016; 25: 75–80.

41.

Zamora

Warner

Tuder

, et al. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine 1997; 76: 192–202.

42.

Lara

Schwarz

MI.

Diffuse alveolar hemorrhage. Chest 2010; 137: 1164–1171.

43.

Hughson

Henegar

, et al. Alveolar hemorrhage and renal microangiopathy in systemic lupus erythematosus. Arch Pathol Lab Med 2001; 125: 475–483.

44.

Bajema

Wilhelmus

Alpers

CE.

Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 2018; 93: 789–796.

45.

Sun

Zhou

Zhao

, et al. Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China. Lupus 2020; 29: 795–803.

46.

Cartin-Ceba

Peikert

Ashrani

, et al. Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage. Arthritis Care Res 2014; 66: 301–310.

47.

Myers

Katzenstein

AA.

Microangiitis in lupus-induced pulmonary hemorrhage. Am J Clin Pathol 1986; 85: 552–556.

48.

Al-Adhoubi

Bystrom

Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies. Lupus 2020; 29: 355–363.

49.

Zhuang

Han

Lee

, et al. Pathogenesis of diffuse alveolar hemorrhage in murine lupus. Arthritis Rheum 2017; 69: 1280–1293.

50.

Barile

Jara

Medina-Rodriguez

, et al. Pulmonary hemorrhage in systemic lupus erythematosus. Lupus 1997; 6: 445–448.

51.

Ednalino

Yip

Carsons

SE.

Systematic review of diffuse alveolar hemorrhage in systemic lupus erythematosus: focus on outcome and therapy. J Clin Rheumatol 2015; 21: 305–310.

52.

Virdi

Bashir

Shahzad

, et al. Diffuse alveolar hemorrhage: a rare life-threatening condition in systemic lupus erythematosus. Case Rep Pulmonol 2012; 2012: 836017.

53.

Iaccarino

Bartoloni

Carli

, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol 2015; 33: 449–456.

54.

Hannah

D’Cruz

DP.

Pulmonary complications of systemic lupus erythematosus. Semin Respir Crit Care Med 2019; 40: 227–234.

55.

Gatto

Zen

Iaccarino

, et al. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 2019; 15: 30–48.

56.

Cheema

Quismorio

Jr.

Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med 2000; 6: 424–429.

57.

Wiedemann

Matthay

RA.

Pulmonary manifestations of systemic lupus erythematosus. J Thorac Imaging 1992; 7: 1–18.

58.

Weinrib

Sharma

Quismorio

Jr.

A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20: 48–56.

59.

Yee

Hussein

Skan

, et al. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 2003; 42: 276–279.

60.

Medlin

Hansen

McCoy

, et al. Pulmonary manifestations in late versus early systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum 2018; 48: 198–204.

61.

Pons-Estel

Ugarte-Gil

Alarcón

GS.

Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol 2017; 13: 799–814.

62.

Tansey

Wells

Colby

, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44: 585–596.

63.

Takada

Saito

Nomura

, et al. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in systemic lupus erythematosus. Pediatr Pulmonol 2005; 40: 257–260.

64.

Hedgpeth

Boulware

DW.

Interstitial pneumonitis in antinuclear antibody-negative systemic lupus erythematosus: a new clinical manifestation and possible association with anti-Ro (SS-A) antibodies. Arthritis Rheum 1988; 31: 545–548.

65.

Bao

Zhang

Shi

, et al. Correlation between serum tumor marker levels and connective tissue disease-related interstitial lung disease. Int J Gen Med 2021; 14: 2553–2560.

66.

Flaherty

Wells

Cottin

, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718–1727.

67.

Wells

Flaherty

Brown

, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8: 453–460.

68.

Lim

Gillis

Smith

, et al. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Intern Med J 2006; 36: 260–262.

69.

Okada

Suzuki

Matsumoto

, et al. Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases. Mod Rheumatol 2007; 17: 131–136.

70.

Swigris

Olson

Fischer

, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130: 30–36.

71.

Yusuf

Hooper

Grosse

, et al. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res 2015; 135: 50–57.

72.

Yusuf

Hooper

Beckman

, et al. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis 2014; 38: 306–313.

73.

Wahl

Guillemin

de Maistre

, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—a meta-analysis. Lupus 1997; 6: 467–473.

74.

Ghirardello

Doria

Ruffatti

, et al. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? Ann Rheum Dis 1994; 53: 140–142.

75.

Larosa

Iaccarino

Gatto

, et al. Advances in the diagnosis and classification of systemic lupus erythematosus. Expert Rev Clin Immunol 2016; 12: 1309–1320.

76.

Zen

Martinez

Benvenuti

, et al. Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion. Rheumatology 2021; 60: 1313–1320.

77.

Johnson

Granton

JT.

Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 2011; 20: 277–286.

78.

Pope

An update in pulmonary hypertension in systemic lupus erythematosus—do we need to know about it?

Lupus 2008; 17: 274–277.

79.

Montani

Achouh

Dorfmüller

, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine 2008; 87: 220–233.

80.

Zanatta

Polito

Famoso

, et al. Pulmonary arterial hypertension in connective tissue disorders: pathophysiology and treatment. Exp Biol Med 2019; 244: 120–131.

81.

Prabu

Patel

Yee

, et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology 2009; 48: 1506–1511.

82.

Doria

Iaccarino

Sarzi-Puttini

, et al. Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14: 683–686.

83.

Tam

LS.

Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 1999; 26: 1923–1929.

84.

Shen

Chen

, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 1999; 18: 147–151.

85.

Guillevin

Vasculopathy and pulmonary arterial hypertension. Rheumatology 2009; 48(Suppl. 3): iii54–iii57.

86.

Yang

Guo

Pudasaini

, et al. Value of heart rate recovery in female patients with pulmonary arterial hypertension due to systemic lupus erythematosus. Clin Respir J 2019; 13: 545–554.

87.

Quismorio

Jr Sharma

Koss

, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984; 13: 349–359.

88.

Dhala

Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol 2012; 2012: 854941.

89.

Roncoroni

Alvarez

Molinas

Plexogenic arteriopathy associated with pulmonary vasculitis in systemic lupus erythematosus. Respiration 1992; 59: 52–56.

90.

Maron

Galiè

Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: a review. JAMA Cardiol 2016; 1: 1056–1065.

91.

Badesch

Hill

Burgess

, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007; 34: 2417–2422.

92.

Galiè

Barberà

Frost

, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–844.

93.

Jais

Launay

Yaici

, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521–531.

94.

Gonzalez-Lopez

Cardona-Muñoz

Celis

, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 2004; 13: 105–112.

95.

Hennigan

Channick

Silverman

GJ.

Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus 2008; 17: 754–756.

96.

Bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension, 2016, https://clinicaltrials.gov/ct2/show/NCT02657356?term=connective+tissue+disease&cond=Pulmonary+Arterial+Hypertension&draw=2&rank=1

97.

Smyth

Flood

Kane

, et al. Shrinking lung syndrome and systemic lupus erythematosus: a case series and literature review. QJM 2018; 111: 839–843.

98.

Uslu

Avşar

Erez

, et al. Shrinking lung syndrome in primary Sjögren syndrome. Balkan Med J 2020; 37: 351–352.

99.

Borrell

Narváez

Alegre

, et al. Shrinking lung syndrome in systemic lupus erythematosus: a case series and review of the literature. Medicine 2016; 95: e4626.

100.

Munoz

Gelber

Houston

BA.

Into thin air: shrinking lung syndrome. Am J Med 2014; 127: 711–713.

101.

Allen

Fischer

Bshouty

, et al. Evaluating systemic lupus erythematosus patients for lung involvement. Lupus 2012; 21: 1316–1325.

102.

Carmier

Diot

Shrinking lung syndrome: recognition, pathophysiology and therapeutic strategy. Expert Rev Respir Med 2011; 5: 33–39.

103.

Rubin

Urowitz

MB.

Shrinking lung syndrome in SLE—a clinical pathologic study. J Rheumatol 1983; 10: 973–976.

104.

Hawkins

Davison

Dasgupta

, et al. Diaphragm strength in acute systemic lupus erythematosus in a patient with paradoxical abdominal motion and reduced lung volumes. Thorax 2001; 56: 329–330.

105.

Laroche

Mulvey

Hawkins

, et al. Diaphragm strength in the shrinking lung syndrome of systemic lupus erythematosus. Q J Med 1989; 71: 429–439.

106.

Hardy

Herry

Attali

, et al. Bilateral phrenic paralysis in a patient with systemic lupus erythematosus. Chest 2001; 119: 1274–1277.

107.

Henderson

Loring

Gill

, et al. Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. J Rheumatol 2013; 40: 273–281.

108.

Toya

Tzelepis

GE.

Association of the shrinking lung syndrome in systemic lupus erythematosus with pleurisy: a systematic review. Semin Arthritis Rheum 2009; 39: 30–37.

109.

Karim

Miranda

Tench

, et al. Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum 2002; 31: 289–298.

110.

Soubrier

Dubost

Piette

, et al. Shrinking lung syndrome in systemic lupus erythematosus. A report of three cases. Rev Rhum Engl Ed 1995; 62: 395–398.

111.

Benham

Garske

Vecchio

, et al. Successful treatment of shrinking lung syndrome with rituximab in a patient with systemic lupus erythematosus. J Clin Rheumatol 2010; 16: 68–70.

112.

Peñacoba Toribio

Córica Albani

Mayos Pérez

, et al. Rituximab in the treatment of shrinking lung syndrome in systemic lupus erythematosus. Reumatol Clin 2014; 10: 325–327.

113.

Langenskiöld

Bonetti

Fitting

, et al. Shrinking lung syndrome successfully treated with rituximab and cyclophosphamide. Respiration 2012; 84: 144–149.

114.

Muñoz-Rodríguez

Font

Badia

, et al. Shrinking lungs syndrome in systemic lupus erythematosus: improvement with inhaled beta-agonist therapy. Lupus 1997; 6: 412–414.

115.

Navarro-Zarza

Alvarez-Hernández

Casasola-Vargas

, et al. Prevalence of community-acquired and nosocomial infections in hospitalized patients with systemic lupus erythematosus. Lupus 2010; 19: 43–48.

116.

Zen

Saccon

Gatto

Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. Rheumatology 2020; 59: 1591–1598.

117.

Doria

Iaccarino

Ghirardello

, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 700–706.

118.

Petri

Genovese

Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. J Rheumatol 1992; 19: 1559–1565.

119.

Doria

Canova

Tonon

, et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 2008; 8: 24–28.

120.

Piliero

Furie

Functional asplenia in systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20: 185–189.

121.

Duffy

Gladman

DD.

Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 1991; 18: 1180–1184.

122.

Ramos-Casals

Cuadrado

Alba

, et al. Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine 2008; 87: 311–318.

123.

Weng

Liu

Weng

, et al. Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan. J Clin Rheumatol 2013; 19: 252–258.

124.

Furer

Rondaan

Heijstek

, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79: 39–52.

125.

Tincani

Andreoli

Cavazzana

, et al. Novel aspects of Sjögren’s syndrome in 2012. BMC Med 2013; 11: 93.

126.

Baldini

Pepe

Quartuccio

, et al. Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology 2014; 53: 839–844.

127.

Manfrè

Cafaro

Riccucci

, et al. One year in review 2020: comorbidities, diagnosis and treatment of primary Sjögren’s syndrome. Clin Exp Rheumatol 2020; 38(Suppl. 126): 10–22.

128.

Jin

Zhang

, et al. Clinical profile and associated factors of pulmonary involvement in primary Sjögren’s syndrome. Med Clin 2019; 153: 305–311.

129.

Manuel

Pilar

Raphaèle

, et al. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 2015; 54: 2230–2238.

130.

Strimlan

Rosenow

Divertie

, et al. Pulmonary manifestations of Sjögren’s syndrome. Chest 1976; 70: 354–361.

131.

García-Carrasco

Ramos-Casals

Rosas

, et al. Primary Sjögren syndrome. Medicine 2002; 81: 270–280.

132.

Natalini

Johr

Kreider

Pulmonary involvement in Sjögren syndrome. Clin Chest Med 2019; 40: 531–544.

133.

Heus

Arends

Van Nimwegen

, et al. Pulmonary involvement in primary Sjögren’s syndrome, as measured by the ESSDAI. Scand J Rheumatol 2020; 49: 38–46.

134.

Mandl

Diaz

Ekberg

, et al. Frequent development of chronic obstructive pulmonary disease in primary SS—results of a longitudinal follow-up. Rheumatology 2012; 51: 941–946.

135.

Strevens Bolmgren

Olsson

Wollmer

, et al. Respiratory symptoms are poor predictors of concomitant chronic obstructive pulmonary disease in patients with primary Sjögren’s syndrome. Rheumatol Int 2017; 37: 813–818.

136.

Kampolis

Fragkioudaki

Mavragani

, et al. Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren’s syndrome. Clin Exp Rheumatol 2018; 36(Suppl. 112): 94–101.

137.

Gudbjornsson

Hedenstrom

Stalenheim

, et al. Bronchial hyperresponsiveness to methacholine in patients with primary Sjogren’s syndrome. Ann Rheum Dis 1991; 50: 36–40.

138.

Shen

Chen

Wei

, et al. Risk of asthma in patients with primary Sjögren’s syndrome: a retrospective cohort study. BMC Pulm Med 2016; 16: 152.

139.

Gupta

Ferrada

Hasni

SA.

Pulmonary manifestations of primary Sjögren’s syndrome: underlying immunological mechanisms, clinical presentation, and management. Front Immunol 2019; 10: 1327.

140.

Ito

Nagai

Kitaichi

, et al. Pulmonary manifestations of primary Sjogren’s syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171: 632–638.

141.

Borie

Schneider

Debray

, et al. Severe chronic bronchiolitis as the presenting feature of primary Sjögren’s syndrome. Respir Med 2011; 105: 130–136.

142.

Wight

Baqir

Ryu

JH.

Constrictive bronchiolitis in patients with primary Sjögren syndrome. J Clin Rheumatol 2019; 25: 74–77.

143.

Wells

Du Bois

RM.

Bronchiolitis in association with connective tissue disorders. Clin Chest Med 1993; 14: 655–666.

144.

Ryu

Myers

Swensen

SJ.

Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168: 1277–1292.

145.

Lee

Scofield

Hammitt

, et al. Consensus guidelines for evaluation and management of pulmonary disease in Sjögren’s. Chest 2021; 159: 683–698.

146.

Stojan

Baer

Danoff

SK.

Pulmonary manifestations of Sjögren’s syndrome. Curr Allergy Asthma Rep 2013; 13: 354–360.

147.

Gottenberg

Cinquetti

Larroche

, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013; 72: 1026–1031.

148.

Aerni

Vassallo

Myers

, et al. Follicular bronchiolitis in surgical lung biopsies: clinical implications in 12 patients. Respir Med 2008; 102: 307–312.

149.

Flament

Bigot

Chaigne

, et al. Pulmonary manifestations of Sjögren’s syndrome. Eur Respir Rev 2016; 25: 110–123.

150.

Gardiner

Ward

Allison

, et al. Pleuropulmonary abnormalities in primary Sjögren’s syndrome. J Rheumatol 1993; 20: 831–837.

151.

Lohrmann

Uhl

Warnatz

, et al. High-resolution CT imaging of the lung for patients with primary Sjogren’s syndrome. Eur J Radiol 2004; 52: 137–143.

152.

Soto-Cardenas

Perez-De-Lis

Bove

, et al. Bronchiectasis in primary Sjögren’s syndrome: prevalence and clinical significance. Clin Exp Rheumatol 2010; 28: 647–653.

153.

Silva

Milanese

Seletti

, et al. Pulmonary quantitative CT imaging in focal and diffuse disease: current research and clinical applications. Br J Radiol 2018; 91: 20170644.

154.

Sambataro

Ferro

Orlandi

, et al. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjögren’s syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev 2020; 19: 102447.

155.

Roca

Dominique

Schmidt

, et al. Interstitial lung disease in primary Sjögren’s syndrome. Autoimmun Rev 2017; 16: 48–54.

156.

Luppi

Sebastiani

Silva

, et al. Interstitial lung disease in Sjögren’s syndrome: a clinical review. Clin Exp Rheumatol 2020; 38(Suppl. 126): 291–300.

157.

Wang

Hou

Qiu

, et al. Risk factors for primary Sjögren syndrome-associated interstitial lung disease. J Thorac Dis 2018; 10: 2108–2117.

158.

Dong

Zhou

Guo

, et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol 2018; 37: 2981–2988.

159.

Gao

Zou

Zhang

, et al. Interstitial lung disease in non-sicca onset primary Sjögren’s syndrome: a large-scale case-control study. Int J Rheum Dis 2018; 21: 1423–1429.

160.

Uffmann

Kiener

Bankier

, et al. Lung manifestation in asymptomatic patients with primary Sjögren syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging 2001; 16: 282–289.

161.

Ciancio

Pavone

Torrisi

, et al. Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. Multidiscip Respir Med 2019; 14: 17, https://mrmjournal.biomedcentral.com/articles/10.1186/s40248-019-0179-2

162.

Parambil

Myers

Lindell

, et al. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130: 1489–1495.

163.

Watanabe

Koyama

Miwa

, et al. Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in Sjögren’s syndrome showing only the LIP pattern radiologically. Intern Med 2012; 51: 491–495.

164.

Travis

WD.

Rare diseases bullet 13: non-neoplastic pulmonary lymphoid lesions. Thorax 2001; 56: 964–971.

165.

Ramos-Casals

Brito-Zerón

Bombardieri

, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis 2020; 79: 3–18.

166.

Flaherty

Thwaite

Kazerooni

, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143–148.

167.

Matteson

Ike

RW.

Bronchiolitis obliterans organizing pneumonia and Sjögren’s syndrome. J Rheumatol 1990; 17: 676–679.

168.

Justet

Ottaviani

Dieudé

, et al. Tocilizumab for refractory organising pneumonia associated with Sjögren’s disease. BMJ Case Rep 2015; 2015: bcr2014209076.

169.

Cha

Fessler

Cool

, et al. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J 2006; 28: 364–369.

170.

De Vita

Quartuccio

Salvin

, et al. Sequential therapy with belimumab followed by rituximab in Sjögren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol 2014; 32: 490–494.

171.

Saadoun

Ghembaza

Riviere

, et al. Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: a pilot study. J Autoimmun 2021; 116: 102577.

172.

Chevalier

Belkhir

Seror

, et al. Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone. Ann Rheum Dis 2020; 79: 1257–1259.

173.

Safety and efficacy study of subcutaneous belimumab and intravenous rituximab co-administration in subjects with primary Sjogren’s syndrome, 2015, https://clinicaltrials.gov/ct2/show/NCT02631538

174.

Gandolfo

De Vita

Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjögren’s syndrome. Clin Exp Rheumatol 2019; 37(Suppl. 118): 199–208.

175.

Safety and efficacy of VAY736 in patients with primary Sjogren’s syndrome (pSS), 2016, https://clinicaltrials.gov/ct2/show/NCT02962895

176.

Mavragani

Moutsopoulos

HM.

Sjögren’s syndrome: old and new therapeutic targets. J Autoimmun 2020; 110: 102364.

177.

Safety, pharmacokinetics and preliminary efficacy study of CFZ533 in patients with primary Sjögren’s syndrome, 2014, https://clinicaltrials.gov/ct2/show/NCT02291029

178.

Mieliauskaite

Dumalakiene

Rugiene

, et al. Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren’s syndrome. Clin Dev Immunol 2012; 2012: 187258.

179.

Brkic

Maria

van Helden-Meeuwsen

, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren’s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013; 72: 728–735.

180.

Furie

Khamashta

Merrill

, et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheum 2017; 69: 376–386.

181.

Del Papa

Minniti

Lorini

, et al. The role of interferons in the pathogenesis of Sjögren’s syndrome and future therapeutic perspectives. Biomolecules 2021; 11: 251.

182.

Lee

Kwok

, et al. JAK-1 inhibition suppresses interferon-induced BAFF production in human salivary gland: potential therapeutic strategy for primary Sjögren’s syndrome. Arthritis Rheum 2018; 70: 2057–2066.

183.

Barnes

PJ.

Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Pharmacol Rev 2016; 68: 788–815.

184.

Milara

Hernandez

Ballester

, et al. The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir Res 2018; 19: 24.

185.

Chen

Chou

Lai

, et al. Lung involvement in primary Sjögren’s syndrome: correlation between high-resolution computed tomography score and mortality. J Chin Med Assoc 2014; 77: 75–82.

186.

Enomoto

Takemura

Hagiwara

, et al. Prognostic factors in interstitial lung disease associated with primary Sjögren’s syndrome: a retrospective analysis of 33 pathologically–proven cases. PLoS ONE 2013; 8: e73774.

187.

Kolb

Bondue

Pesci

, et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27: 180071.

188.

Spagnolo

Distler

Ryerson

, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis 2021; 80: 143–150.

189.

Leuschner

Behr

Acute exacerbation in interstitial lung disease. Front Med 2017; 4: 176.

190.

Richeldi

Cottin

du Bois

, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med 2016; 113: 74–79.

191.

Kassan

Thomas

Moutsopoulos

, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 888–892.

192.

Borie

Wislez

Thabut

, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J 2009; 34: 1408–1416.

193.

Voulgarelis

Dafni

Isenberg

, et al. Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s syndrome. Arthritis Rheum 1999; 42: 1765–1772.

194.

De Vita

Gandolfo

. Predicting lymphoma development in patients with Sjögren’s syndrome. Expert Rev Clin Immunol 2019; 15: 929–938.

195.

Yachoui

Leon

Sitwala

, et al. Pulmonary MALT lymphoma in patients with Sjögren’s syndrome. Clin Med Res 2017; 15: 6–12.

196.

Tzioufas

Voulgarelis

Update on Sjögren’s syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007; 21: 989–1010.

197.

Quartuccio

Isola

Corazza

, et al. Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol 2012; 30(1, Suppl. 70): S48–S52.

198.

Quartuccio

Isola

Baldini

, et al. Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2014; 51: 75–80.

199.

Chen

Cao

Lin

, et al. Biomarkers for primary Sjögren’s syndrome. Genomics Proteomics Bioinformatics 2015; 13: 219–223.

200.

Gasparotto

De Vita

De Re

, et al. Extrasalivary lymphoma development in Sjögren’s syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum 2003; 48: 3181–3186.

201.

Bae

Lee

Han

, et al. Marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue. Chest 2008; 133: 433–440.

202.

Papiris

Kalomenidis

Malagari

, et al. Extranodal marginal zone B-cell lymphoma of the lung in Sjögren’s syndrome patients: reappraisal of clinical, radiological, and pathology findings. Respir Med 2007; 101: 84–92.

203.

Egashira

Kondo

Hirai

, et al. CT findings of thoracic manifestations of primary Sjögren syndrome: radiologic-pathologic correlation. Radiographics 2013; 33: 1933–1949.

204.

Graham

Mathisen

Mark

, et al. Primary pulmonary lymphoma. Ann Thorac Surg 2005; 80: 1248–1253.

205.

Gribben

JG.

How I treat indolent lymphoma. Blood 2007; 109: 4617–4626.

206.

Brito-Zerón

Baldini

Bootsma

, et al. Sjögren syndrome. Nat Rev Dis Primers 2016; 72: 16047.

207.

De Vita

Boiocchi

Sorrentino

, et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren’s syndrome. Arthritis Rheum 1997; 40: 318–331.

208.

Chung

Wilgus

Fishbein

, et al. Pulmonary and Bronchiolar Involvement in Sjogren’s syndrome. Semin Respir Crit Care Med 2019; 40: 235–254.

209.

Song

Seol

Park

, et al. Pulmonary nodular lymphoid hyperplasia associated with Sjögren’s syndrome. Korean J Intern Med 2007; 22: 192–196.

210.

Hansen

Prakash

UBS

Colby

TV.

Pulmonary lymphoma in Sjögren’s syndrome. Mayo Clin Proc 1989; 64: 920–931.

211.

Milani

Basset

Russo

, et al. The lung in amyloidosis. Eur Respir Rev 2017; 26: 170046.

212.

Rajagopala

Singh

Gupta

, et al. Pulmonary amyloidosis in Sjogren’s syndrome: a case report and systematic review of the literature. Respirology 2010; 15: 860–866.

213.

Bonner

Jr Ennis

Geelhoed

, et al. Lymphoid infiltration and amyloidosis of lung in Sjögren’s syndrome. Arch Pathol 1973; 95: 42–44.

214.

Srinivas

Liam

Jayaram

Localised nodular pulmonary amyloidosis in a patient with sicca syndrome. Med J Malaysia 2000; 55: 385–387.

215.

Desai

Nicholson

Stewart

, et al. Benign pulmonary lymphocytic infiltration and amyloidosis: computed tomographic and pathologic features in three cases. J Thorac Imaging 1997; 12: 215–220.

216.

Subcutaneous masses and adenopathy in a 77-year-old man with Sjögren’s syndrome and amyloidosis. Am J Med 1989; 86: 585–590, https://www.semanticscholar.org/paper/Subcutaneous-masses-and-adenopathy-in-a-77-year-old/c43c8b74e0355e9d886a95c86af9572abec1ccd6#citing-papers

217.

Hosono

Bando

Suzuki

, et al. Sjögren’s syndrome with multiple bullae due to pulmonary nodular amyloidosis. Nihon Kokyuki Gakkai Zasshi 2007; 45: 869–873.

218.

Niepolski

Grzegorzewska

Szymaś

Nodular pulmonary amyloidosis and Sjögren’s syndrome in a patient treated with intermittent hemodialysis. Hemodial Int 2007; 11: 406–410.

219.

Lantuejoul

Moulai

Quetant

, et al. Unusual cystic presentation of pulmonary nodular amyloidosis associated with MALT-type lymphoma. Eur Respir J 2007; 30: 589–592.

220.

Chien

YC.

Sjögren’s syndrome with nodular pulmonary amyloidosis. Respirol Case Rep 2020; 9: e00699.

221.

Jeong

Lee

Chung

, et al. Amyloidosis and lymphoproliferative disease in Sjögren syndrome: thin-section computed tomography findings and histopathologic comparisons. J Comput Assist Tomogr 2004; 28: 776–781.

222.

Nakamura

Yamada

Itoh

, et al. Pulmonary MALT lymphoma with amyloid production in a patient with primary Sjögren’s syndrome. Intern Med 2002; 41: 309–311.

223.

Srivali

Ungprasert

Cheungpasitporn

, et al. Lung cavities in Sjögren’s syndrome. QJM 2016; 109: 135–136.

224.

Watanabe

Naniwa

Hara

, et al. Pulmonary manifestations in Sjögren’s syndrome: correlation analysis between chest computed tomographic findings and clinical subsets with poor prognosis in 80 patients. J Rheumatol 2010; 37: 365–373.

225.

Lechtman

Debray

Crestani

, et al. Cystic lung disease in Sjögren’s syndrome: an observational study. Joint Bone Spine 2017; 84: 317–321.

226.

Gal

Kovacs

Zeher

Case series: coexistence of Sjögren’s syndrome and sarcoidosis. J Rheumatol 2000; 27: 2507–2510.

227.

Ramos-Casals

Brito-Zerón

García-Carrasco

, et al. Sarcoidosis or Sjögren syndrome? Medicine 2004; 83: 85–95.

228.

Santiago

Rovisco

, et al. Coexisting primary Sjögren’s syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome? Rheumatol Int 2014; 34: 1619–1622.

229.

Zabotti

Zandonella Callegher

Lorenzon

, et al. Ultrasound-guided core needle biopsy compared with open biopsy: a new diagnostic approach to salivary gland enlargement in Sjögren’s syndrome? Rheumatology 2021; 60: 1282–1290.

230.

Aviña-Zubieta

Jansz

Sayre

, et al. The risk of deep venous thrombosis and pulmonary embolism in primary Sjögren syndrome: a general population-based study. J Rheumatol 2017; 44: 1184–1189.

231.

Quartuccio

Risk of thrombosis in Sjögren syndrome: the open question of endothelial function immune-mediated dysregulation. J Rheumatol 2017; 44: 1106–1108.

232.

Pasoto

Chakkour

Natalino

, et al. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren’s syndrome. Clin Rheumatol 2012; 31: 1331–1338.

233.

Launay

Hachulla

Hatron

, et al. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine 2007; 86: 299–315.

234.

Naniwa

Takeda

Long-term remission of pulmonary veno-occlusive disease associated with primary Sjögren’s syndrome following immunosuppressive therapy. Mod Rheumatol 2011; 21: 637–640.

235.

Vassiliou

Moyssakis

Boki

, et al. Is the heart affected in primary Sjögren’s syndrome? An echocardiographic study. Clin Exp Rheumatol 2008; 26: 109–112.

236.

Kobak

Kalkan

Kirilmaz

, et al. Pulmonary arterial hypertension in patients with primary Sjögren’s syndrome. Autoimmune Dis 2014; 2014: 710401.

237.

Galiè

Humbert

Vachiery

, et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37: 67–119.

238.

Wang

, et al. Pulmonary arterial hypertension associated with primary Sjögren’s syndrome: a multicentre cohort study from China. Eur Respir J 2020; 56: 1902157.

239.

Yan

Wang

, et al. Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjögren’s syndrome. Int J Rheum Dis 2018; 21: 1068–1075.

240.

Zhao

Wang

Liu

, et al. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: a cohort study in China. Int J Cardiol 2017; 236: 432–437.

241.

Nakagawa

Osanai

Ide

, et al. Severe pulmonary hypertension associated with primary Sjögren’s syndrome. Intern Med 2003; 42: 1248–1252.

242.

Liu

Yang

Tian

, et al. The prognosis of pulmonary arterial hypertension associated with primary Sjögren’s syndrome: a cohort study. Lupus 2018; 27: 1072–1080.

243.

Hwang

Yang

Lee

, et al. Severe pulmonary hypertension in primary Sjögren’s syndrome. Korean Circ J 2013; 43: 504–507.

244.

Makimoto

Asano

Fujimoto

, et al. Bilateral pleural effusions as an initial presentation in primary Sjögren’s syndrome. Case Rep Rheumatol 2012; 2012: 640353.

245.

Teshigawara

Kakizaki

Horiya

, et al. Primary Sjogren’s syndrome complicated by bilateral pleural effusion. Respirology 2008; 13: 155–158.

246.

Blanco

Pérez JJ

Pérez

González A

Guerra

Vales JL

, et al. Shrinking lung in primary Sjogrën syndrome successfully treated with rituximab. Arch Bronconeumol 2015; 51: 475–476.

247.

Martínez-Granados

Delgado-García

Wah-Suárez

, et al. Primary Sjögren’s syndrome first presenting as hypokalemic quadriparesis. Arch Rheumatol 2017; 32: 257–259.

248.

Sorajja

Poirier

Bundrick

, et al. Autonomic failure and proximal skeletal myopathy in a patient with primary Sjögren syndrome. Mayo Clin Proc 1999; 74: 695–697.

249.

Koga

Kouhisa

Nakamura

, et al. A case of primary Sjögren’s syndrome complicated with inflammatory myopathy and interstitial lung disease. Rheumatol Int 2012; 32: 3647–3649.